Claims
- 1. A process for forming a single stranded circular oligonucleotide comprising contacting 3′-hydroxyl and 5′-phosphorothioate groups of an open circle oligonucleotide (OCO), having such groups at its 3′- and 5′-ends, with a bridging oligonucleotide (BO), said BO comprising sequences complementary to sequences at the 3′- and 5′-ends of said OCO, in the presence of a ligation catalyst that directs formation of a 3′-5′-phosphodiester linkage with the sulfur atom of said 5′-phosphorothioate group not present as a bridging atom thereby forming a single-stranded circular oligonucleotide.
- 2. The process of claim 1 wherein said catalyst is N-ethyl-N′-(dimethylaminopropyl)-carbodiimide hydrochloride (EDC).
- 3. The process of claim 1 wherein said catalyst is an enzyme.
- 4. The process of claim 3 wherein said enzyme is a ligase.
- 5 The process of claim 4 wherein said ligase is a ligase that forms phosphodiester linkages at nicks in duplex DNA containing phosphorothioate at a 5′-end of said nick.
- 6. The process of claim 5 wherein said ligase is selected from the group consisting of T4 DNA ligase, E. coli DNA ligase, Taq DNA ligase, Tth DNA ligase, Thermus scotoductus DNA ligase, Rhodothermus marinus DNA ligase, Ampligase, Bst ligase, T4 RNA ligase and cappases.
- 7. The process of claim 6 wherein said ligase is present along with ATP and NAD.
- 8. The process of claim 7 wherein said ligase is T4 DNA ligase and Ampligase.
- 9. The process of claim 1 further comprising the step of removing said bridging oligonucleotide from said closed circular oligonucleotide.
- 10. The process of claim 1 wherein said OCO and said BO are annealed prior to contacting said 3′-OH and 5′-phosphorothioate groups.
- 11. The process of claim 1 wherein said BO and said OCO are present in the mole ratio of about 1 to 1, respectively.
- 12. The process of claim 1 wherein the molar concentration of BO is greater than that of OCO.
- 13. The process of claim 1 wherein said OCO and said BO are deoxyribonucleotides.
- 14. The process of claim 1 wherein said OCO is a DNA and said BO is RNA.
- 15. The closed circle oligonucleotide formed by the process of claim 1.
- 16. The closed circle of claim 15 wherein said closed circle is conjugated with peptides, proteins, detection labels and primer sequences.
- 17. A process for amplifying a selected oligonucleotide sequence comprising rolling circle amplification (RCA) using an amplification target circle (ATC) formed by the process of claim 1.
- 18. A process for amplifying a selected oligonucleotide sequence comprising rolling circle amplification (RCA) using an amplification target circle (ATC) formed by the process of claim 1.
- 19. The process of claim 1 wherein said bridging oligonucleotide complementary sequences include a nucleotide complementary to either the 3′-nucleotide of said OCO or the 5′-nucleotide of said OCO.
- 20. The process of claim 1 wherein said bridging oligonucleotide complementary sequences include a nucleotide complementary to the 3′-OH nucleotide of said OCO and a nucleotide complementary to the 5′-nucleotide of the OCO.
- 21. A process for detecting nucleotide mismatches comprising:
contacting a first oligonucleotide, comprising first and second segments, with a second oligonucleotide wherein said second oligonucleotide comprises a first complementary segment, a second complementary segment, and a third segment and wherein said second oligonucleotide also comprises a phosphorothioate at its 5′-terminus, and wherein said first and second complementary segments of said second oligonucleotide are complementary to the first and second segments of said first oligonucleotide one of which first oligonucleotide segments comprises at least one mismatched nucleotide, and wherein said third segment is not complementary to said first oligonucleotide, and wherein said contacting occurs under conditions promoting hybridization of said first and second segments with said first and second complementary segments, and wherein said hybridization results in the formation of a complex in which the 5′- and 3′-ends of said second oligonucleotide are adjacent to each other, and said 3′-nucleotide may be opposite a mismatched nucleotide of said first oligonucleotide, contacting said hybridized complex with a ligation catalyst under conditions promoting ligation of the 5′- and 3′-ends of said second oligonucleotide in said hybridized complex when said mismatch is not present, and detecting formation of ligated second oligonucleotide wherein reduced or non-formation thereof indicates the presence of a nucleotide mismatch.
- 22. The process of claim 21 wherein said ligation catalyst is an enzyme.
- 23. The process of claim 22 wherein said enzyme is selected from the group consisting of Ampligase, T4 ligase and T4 RNA ligase.
- 24. The process of claim 23 wherein said enzyme is reacted in the presence of ATP.
- 25. The process of claim 21 further comprising detecting the occurrence of ligated second oligonucleotide by contacting the third segment of ligated second oligonucleotide with a primer oligonucleotide complementary to said third segment under conditions promoting hybridization of said primer to said third segment and further contacting said complex with a rolling circle amplification (RCA) enzyme under conditions promoting rolling circle amplification of said ligated second oligonucleotide.
- 26. The process of claim 25 wherein said rolling circle amplification is exponential rolling circle amplification (ERCA).
- 27. The process of claim 25 wherein said RCA enzyme is a member selected from the group consisting of E. coli DNA polymerase 1, Klenow fragment, T4 or T7 DNA polymerases, Phi 29 DNA polymerase and Taq polymerase.
- 28. The process of claim 26 wherein the RCA enzyme is Phi 29 DNA polymerase.
- 29. The process of claim 25 wherein said first oligonucleotide is part of a genomic DNA.
- 30. The process of claim 26 wherein said second oligonucleotide is a hairpin oligonucleotide.
- 31. The process of claim 21 wherein said second oligonucleotide further comprises internal phosphorothioate groups in addition to the 5′-phosphorothioate.
- 32. The process of claim 31 wherein said internal phosphorothioate groups are 2 to 5 in number.
- 33. The process of claim 25 wherein said second oligonucleotide further comprises internal phosphorothioate groups in addition to the 5′-phosphorothioate.
- 34. The process of claim 21 wherein said first oligonucleotide is attached to a solid support.
- 35. The process of claim 30 wherein said support is composed of a member selected from the group consisting of glass and plastic.
Parent Case Info
[0001] This application claims priority of U.S. Provisional Application Serial No. 60/259,918, filed Jan. 5, 2001, the disclosure of which is hereby incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60259918 |
Jan 2001 |
US |